Researchers discovered that when insomnia and depression co-occur, longer pre-treatment objective sleep duration is predictive of remission of both disorders when patients are given a combination of CBTI for insomnia and antidepressant medication for depression.
“A seven-hour, objective sleep duration of patients prior to entering treatment increased their chances of achieving both depression and insomnia remission by their treatment endpoints,” said lead author Jack D. Edinger, Ph.D., professor in the Section of Sleep Medicine at National Jewish Health in Denver, Colorado.
Researchers evaluated 104 adults, including 75 women, who enrolled in the Treatment of Insomnia and Depression Study and completed one baseline night of polysomnography.
Participants received 16 weeks of anti-depressant medication and were randomly assigned either to CBTI or sham insomnia therapy. The Hamilton Rating Scale for Depression (HAMD-17) and Insomnia Severity Index were administered at baseline and then bi-weekly during treatment to determine depression and insomnia remission.
The study was part of a larger research project involving investigators from the University of Pittsburgh, Duke University, University of California, San Francisco; and Stanford University. Rachel Manber, Ph.D., professor of psychiatry and behavioral sciences at the Stanford University Medical Center is the lead principal investigator.
“Our findings highlight the importance of adequate objective sleep in the recovery from depression and insomnia,” said Manber.
“The data suggest that short sleep duration may be a risk for refractory depression.”
The research abstract was published recently in an online supplement of the journal Sleep and will be presented at SLEEP 2017, the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS).